BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advanced Bio-Surfaces, Inc. Release: OrthoGlide(TM) Medial Knee Implant Reports Over 200 Implants


6/7/2007 12:17:38 PM

MINNEAPOLIS, June 7 /PRNewswire-FirstCall/ -- Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer announced today that over 200 implants have been completed in the United States using the OrthoGlide Medial Knee implant. The OrthoGlide is a minimally invasive implant designed to relieve chronic, disabling pain, due to moderate osteoarthritis of the medial compartment of the knee.

"There has been a significant increase in the number of orthopedic surgeons interested in attending the surgeon training programs for the OrthoGlide," said Dr. Jeff Felt, Chairman and CEO of Advanced Bio-Surfaces. "The number of trained surgeons has more than doubled in the last six months, proving that orthopedic surgeons want a minimally invasive knee implant option for their patients with painful osteoarthritis of the knee. Approximately 100 implants were performed during the first 11 months of the commercial availability of OrthoGlide. The second group of 100 implants, which brought the implant total in the United States to 200, was performed within four months. ABS is encouraged by the desire of patients and surgeons to seek an alternative that may delay the need for a total knee replacement."

Orthopaedic surgeon, Dave Trotter, M.D., President and Founder of The Center for Sports Orthopaedics in Chicago, Illinois is one of the most experienced implanters of the OrthoGlide. Dr. Trotter said, "The appeal of the OrthoGlide device is both the relative straightforwardness of the procedure and stability of the implant. Surgeons can offer their patients pain relief, through a minimally invasive bone conserving procedure which requires no screws or cement when compared to total knee and unicompartmental replacements. This new technology can offer positive clinical outcomes to patients and provides a less invasive choice in the continuum of care."

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, in February 2006. For additional information contact ABS at 952.912.5400 or visit the website at http://www.advbiosurf.com.

Advanced Bio-Surfaces, Inc.

CONTACT: Robert Siegfried, VP, Finance and Administration of AdvancedBio-Surfaces, Inc., +1-952-912-5400



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES